Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life

• Main Authors: Tessa Hosman (Author), Roy van Heesbeen (Author), Arangassery Rosemary Bastian (Author), Weihong Hu (Author), Christy Comeaux (Author), Nynke Ligtenberg (Author), Bart van Montfort (Author), Benoît Callendret (Author), Esther Heijnen (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

ABSTRACTThis study assessed three Ad26.RSV.preF/RSV preF protein combinations, combining different Ad26.RSV.preF doses and naturally aged preF protein, representing the expected critical vaccine quality attributes close to release, around intermediate shelf-life (ISL) and near-presumed end-of-shelf-...